| Annual · values | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — | — |
| EBITDA Margin | — | — | — | — | — | — | — | — |
| Net Margin | — | — | — | — | — | — | — | — |
| Current Ratio | 1.97 | 1.31 | 0.83 | 1.66 | 4.31 | 16.41 | 10.62 | — |
| Quick Ratio | 1.97 | 1.31 | 0.83 | 1.66 | 4.31 | 16.41 | 10.62 | — |
| Debt / Equity | 0.15 | 0.97 | -4.95 | 2.19 | 0.00 | — | — | — |
| ROE | -311.39% | -377.69% | 1138.60% | -678.62% | -118.47% | -50.66% | 7.88% | — |
| ROA | -153.18% | -115.08% | -155.25% | -152.31% | -96.31% | -48.61% | -20.46% | — |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
| Book Value / Share | 0.67 | 1.30 | -1.47 | 0.30 | 1.92 | 7.59 | -155.80 | — |
PolyPid Ltd. is an innovative biopharmaceutical company developing long-acting, controlled-release medicines that deliver therapy precisely at the site of care. It specializes in locally administered therapeutics using its proprietary PLEX (Polymer-Lipid Encapsulation matriX) and Kynatrix technologies, which enable precise, localized drug delivery at predetermined rates over days to months. The lead product candidate, D-PLEX100, provides prolonged antibiotic exposure directly at surgical sites to prevent surgical site infections, particularly in abdominal colorectal surgeries. PolyPid Ltd. also advances applications of its platform in oncology, obesity, diabetes, and other high-impact indications, including a long-acting GLP-1 receptor agonist delivery system. The company maintains a GMP-certified manufacturing facility supporting commercial-scale production. Founded in 2008 and headquartered in Petah Tikva, Israel, PolyPid Ltd. focuses on improving patient outcomes in surgical care, metabolic diseases, and beyond through targeted precision drug delivery.